Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration

Abstract

Lipid Nanoparticles (LNPs) are used to deliver siRNA and COVID-19 mRNA vaccines. The main factor known to determine their delivery efficiency is the pKa of the LNP containing an ionizable lipid. Herein, we report a method that can predict the LNP pKa from the structure of the ionizable lipid. We used theoretical, NMR, fluorescent-dye binding, and electrophoretic mobility methods to comprehensively measure protonation of both the ionizable lipid and the formulated LNP. The pKa of the ionizable lipid was 2-3 units higher than the pKa of the LNP primarily due to proton solvation energy differences between the LNP and aqueous medium. We exploited these results to explain a wide range of delivery efficiencies in vitro and in vivo for intramuscular (IM) and intravascular (IV) administration of different ionizable lipids at escalating ionizable lipid-to-mRNA ratios in the LNP. In addition, we determined that more negatively charged LNPs exhibit higher off-target systemic expression of mRNA in the liver following IM administration. This undesirable systemic off-target expression of mRNA-LNP vaccines could be minimized through appropriate design of the ionizable lipid and LNP.

References 55

1. 1.

   Moderna. Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study | Moderna, Inchttps://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy/ (2020).

   Not in our library

2. 2.

   BIONTECH. Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints | BioNTech https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine/ (2020).

   Not in our library

3. 3.

   Cullis PR, Hope MJ. Lipid Nanoparticle Systems for Enabling Gene Therapies. Mol. Ther. 2017;25:1467-1475.

   Not in our library10.1016/j.ymthe.2017.03.013

4. 4.
   How mRNA therapeutics are entering the monoclonal antibody field · 2019

   No notice
5. 5.
   Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing · 2020

   No notice
6. 6.

   Evers MJW, et al. State-of-the-art design and rapid-mixing production techniques of lipid nanoparticles for nucleic acid delivery. Small Methods. 2018;2:1700375.

   Not in our library10.1002/smtd.201700375

7. 7.

   Cheng, Q. et al. Selective Organ Targeting (SORT) Nanoparticles for Tissue-Specific mRNA Delivery and CRISPR–Cas Gene Editing. Nat. Nanotechnol. 10.1038/s41565-020-0669-6 (2020).

   Not in our library10.1038/s41565-020-0669-6

8. 8.

   Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther. Deliv. 2016;7:319-334.

   Not in our library10.4155/tde-2016-0006

9. 9.

   Pardi N, et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J. Exp. Med. 2018;215:1571-1588.

   Not in our library10.1084/jem.20171450

10. 10.

    Akinc A, et al. The onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat. Nanotechnol. 2019;14:1084-1087.

    Not in our library10.1038/s41565-019-0591-y

11. 11.

    Gruner SM, Cullis PR, Hope MJ, Tilcock CPS. Lipid polymorphism: the molecular basis of nonbilayer phases. Annu. Rev. Biophys. Biophys. Chem. 1985;14:211-238.

    Not in our library10.1146/annurev.bb.14.060185.001235

12. 12.

    Witzigmann D, et al. Lipid nanoparticle technology for therapeutic gene regulation in the liver. Adv. Drug Deliv. Rev. 2020.

    Not in our library10.1016/j.addr.2020.06.026

13. 13.

    Hassett KJ, et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol. Ther. Nucleic Acids. 2019;15:1-11.

    Not in our library10.1016/j.omtn.2019.01.013

14. 14.

    Moderna. mRNA-1273-P301-Protocolhttps://www.modernatx.com/sites/default/files/mRNA-1273-P301-Protocol.pdf (2020).

    Not in our library

15. 15.

    Pfizer. Pfizer-BioNTech Covid-19 Vaccine FDA EAU Letter of Authorizationhttps://www.fda.gov/media/144412/download (2020).

    Not in our library

16. 16.

    Kranz LM, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534:396-401.

    Not in our library10.1038/nature18300

17. 17.

    Bahl K, et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol. Ther. 2017;25:1316-1327.

    Not in our library10.1016/j.ymthe.2017.03.035

18. 18.

    Hajj KA, et al. A potent branched-tail lipid nanoparticle enables multiplexed mRNA delivery and gene editing in vivo. Nano Lett. 2020;20:5167-5175.

    Not in our library10.1021/acs.nanolett.0c00596

19. 19.

    Pardi N, et al. Expression kinetics of nucleoside-modified mrna delivered in lipid nanoparticles to mice by various routes. J. Control. Release. 2015;217:345-351.

    Not in our library10.1016/j.jconrel.2015.08.007

20. 20.

    Akinc A, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 2010;18:1357-1364.

    Not in our library10.1038/mt.2010.85

21. 21.

    Walsh, E. E. et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv. 10.1101/2020.08.17.20176651 (2020).

    Not in our library

22. 22.

    Anderson EJ, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N. Engl. J. Med. 2020;383:2427-2438.

    Not in our library10.1056/nejmoa2028436

23. 23.

    Jenne CN, Kubes P. Immune surveillance by the liver. Nat. Immunol. 2013;14:996-1006.

    Not in our library10.1038/ni.2691

24. 24.
    Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo** · 2012

    No notice
25. 25.

    Semple SC, et al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim. Biophys. Acta BBA - Biomembr. 2001;1510:152-166.

    Not in our library10.1016/s0005-2736(00)00343-6

26. 26.

    Heyes J, Palmer L, Bremner K, MacLachlan I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J. Control. Release. 2005;107:276-287.

    Not in our library10.1016/j.jconrel.2005.06.014

27. 27.

    Oregioni A, Stieglitz B, Kelly G, Rittinger K, Frenkiel T. Determination of the PK a of the N-Terminal Amino Group of Ubiquitin by NMR. Sci. Rep. 2017;7:1-8.

    Not in our library10.1038/srep43748

28. 28.

    Katchalsky A, Spitnik P. Potentiometric titrations of polymethacrylic acid. J. Polym. Sci. 1947;2:432-446.

    Not in our library10.1002/pol.1947.120020409

29. 29.

    Filion D, Lavertu M, Buschmann MD. Ionization and solubility of chitosan solutions related to thermosensitive chitosan/glycerol-phosphate systems. Biomacromolecules. 2007;8:3224-3234.

    Not in our library10.1021/bm700520m

30. 30.

    Yanez Arteta M, et al. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles. Proc. Natl Acad. Sci. USA. 2018;115:E3351-E3360.

    Not in our library10.1073/pnas.1720542115

31. 31.

    Eygeris Y, Patel S, Jozic A, Sahay G. Deconvoluting lipid nanoparticle structure for messenger RNA delivery. Nano Lett. 2020.

    Not in our library10.1021/acs.nanolett.0c01386

32. 32.

    Madden, T. D., Tam, Y. K. C., Barbosa, C. J., Mui, B. Lamellar Lipid Nanoparticles. WO2019089828A1. 9 May 2019.

    Not in our library

33. 33.

    Kulkarni JA, et al. On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and SiRNA. ACS Nano. 2018;12:4787-4795.

    Not in our library10.1021/acsnano.8b01516

34. 34.

    Kulkarni JA, et al. Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads. Nanoscale. 2019;11:9023-9031.

    Not in our library10.1039/c9nr02004g

35. 35.

    Fenton OS, et al. Synthesis and biological evaluation of ionizable lipid materials for the in vivo delivery of messenger RNA to B lymphocytes. Adv. Mater. 2017;29:1606944.

    Not in our library10.1002/adma.201606944

36. 36.

    Semple SC, et al. Rational design of cationic lipids for SiRNA delivery. Nat. Biotechnol. 2010;28:172-176.

    Not in our library10.1038/nbt.1602

37. 37.

    Soliman OY, Alameh MG, De Cresenzo G, Buschmann MD, Lavertu M. Efficiency of chitosan/hyaluronan-based mRNA delivery systems in vitro: influence of composition and structure. J. Pharm. Sci. 2020;109:1581-1593.

    Not in our library10.1016/j.xphs.2019.12.020

38. 38.

    Mislick KA, Baldeschwieler JD. Evidence for the role of proteoglycans in cation-mediated gene transfer. Proc. Natl Acad. Sci. USA. 1996;93:12349-12354.

    Not in our library10.1073/pnas.93.22.12349

39. 39.

    Yan X, et al. The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. Biochem. Biophys. Res. Commun. 2005;328:57-62.

    Not in our library10.1016/j.bbrc.2004.12.137

40. 40.

    Weaver, J. C. & Schoenbach, K. H. Biodielectrics. IEEE Transactions on Dielectrics and Electrical Insulation. Vol. 10, p. 715–716 (IEEE, 2003)..

    Not in our library

Cited by papers we hold 1

• Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications · 2024
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.